Head and Neck Cancers (Issue 2)

While medullary thyroid cancer (MTC) is an uncommon malignancy, accounting for about 5% of thyroid cancers, progressive forms of the disease are poorly responsive to chemotherapy and radiation.

Marcia S. Brose, MD, PhD, discusses using both sorafenib and lenvatinib as treatment options for thyroid cancer.

Lori J. Wirth, MD, medical director, Center for Head and Neck Cancers, Massachusetts General Hospital, assistant professor, Harvard Medical School, discusses the side effects of lenvatinib in patients with thyroid cancer.

Barbara Burtness, MD, discusses immune checkpoint inhibitors for head and neck cancers.

The incidence of thyroid cancer in Pennsylvania has grown at a rate significantly higher than that observed in the rest of the country.

A randomized, open-label study is currently under way to test the safety and efficacy of the novel immunoadjuvant, Multikine, in patients with head and neck cancer.

The protein kinase, Wee1, has been identified as a novel therapeutic target for p53-mutant head and neck squamous cell carcinoma (HNSCC).

Expression of the EGFR and its ligand transforming growth factor alpha occurs early in the carcinogenesis of squamous cell carcinoma of the head and neck (SCCHN).